title: Association Between TP53 Gene Codon 72 Polymorphism and Acute Myeloid Leukemia Susceptibility: Evidence Based on a Meta-Analysis.
abstract: BACKGROUND
  Many studies have reported that the p53 codon 72 polymorphism is associated with acute myeloid leukemia (AML) susceptibility; however, the conclusions are inconsistent. Therefore, we performed this meta-analysis to obtain a more precise result.
  
  
  METHODS
  We searched PubMed to identify relevant studies, and 6 published case-control studies were retrieved, including 924 AML patients and 3832 controls. Odds ratio (OR) with corresponding 95% confidence interval (95%CI) was applied to assess the association between p53 codon 72 polymorphism and AML susceptibility. The meta-analysis was performed with Comprehensive Meta-Analysis software, version 2.2.
  
  
  RESULTS
  Overall, no significant association between p53 codon 72 polymorphism and AML susceptibility was found in this meta-analysis (Pro vs. Arg: OR=0.94, 95%CI=0.81-1.10; Pro/Pro vs. Arg/Arg: OR=0.93, 95%CI=0.71-1.22; Arg/Pro vs. Arg/Arg: OR=0.79, 95%CI=0.55-1.13; (Pro/Pro + Arg/Pro) vs. Arg/Arg: OR=0.84, 95%CI=0.62-1.13; Pro/Pro vs. (Arg/Arg + Arg/Pro): OR=1.06, 95%CI=0.83-1.35). Similar results were also found in stratified analysis according to ethnicity and source of controls.
  
  
  CONCLUSIONS
  Our meta-analysis demonstrates that p53 codon 72 polymorphism may not be a risk factor for AML, which should be verified in future studies.
authors.affiliation: Department of Hematology, Targeted Biotherapy Key Laboratory of Ministry of Education, Renmin Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Xiao-Lan
authors.initials: XL
authors.lastname: Ruan
authors.affiliation: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Sheng
authors.initials: S
authors.lastname: Li
authors.affiliation: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, China (mainland).
authors.forename: Peiliang
authors.initials: P
authors.lastname: Geng
authors.affiliation: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Xian-Tao
authors.initials: XT
authors.lastname: Zeng
authors.affiliation: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Guo-Zheng
authors.initials: GZ
authors.lastname: Yu
authors.affiliation: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Xiang-Yu
authors.initials: XY
authors.lastname: Meng
authors.affiliation: Department of Hematology, Targeted Biotherapy Key Laboratory of Ministry of Education, Renmin Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Qing-Ping
authors.initials: QP
authors.lastname: Gao
authors.affiliation: Department of Hematology, Targeted Biotherapy Key Laboratory of Ministry of Education, Renmin Hospital of Wuhan University, Wuhan, Hubei, China (mainland).
authors.forename: Xu-Bin
authors.initials: XB
authors.lastname: Ao
mesh_terms: D016022:Case-Control Studies; D003062:Codon; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D015203:Reproducibility of Results; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D003062:Codon; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53